{"nctId":"NCT03862807","briefTitle":"Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant","startDateStruct":{"date":"2019-03-27","type":"ACTUAL"},"conditions":["Amyloidosis, Familial","Transthyretin Amyloidosis"],"count":24,"armGroups":[{"label":"Patisiran","type":"EXPERIMENTAL","interventionNames":["Drug: Patisiran"]}],"interventions":[{"name":"Patisiran","otherNames":["ALN-TTR02","ONPATTRO"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Received liver transplant for treatment of hATTR amyloidosis ≥12 months before study start\n* Has increase in polyneuropathy disability (PND) score after liver transplant\n* Has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start\n* Has Karnofsky Performance Status (KPS) of ≥70%\n* Has vitamin A level greater than or equal to lower limit of normal\n\nExclusion Criteria:\n\n* Has previously received inotersen or patisiran\n* Has clinically significant liver function test abnormalities\n* Has known portal hypertension with ascites\n* Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m\\^2\n* Has known leptomeningeal amyloidosis\n* Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)\n* Has New York Heart Association heart failure classification of \\>2\n* Is wheelchair bound or bedridden\n* Has received organ transplants other than liver transplant\n* Will be using another tetramer stabilizer during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR)","description":"Serum TTR was assessed using enzyme linked immunosorbent assay (ELISA). The average of the percentage reduction in serum TTR observed at Month 6 and at Month 12 is first calculated for each patient and then the median (95% CI) of these averaged values is summarized for the Safety Analysis Set.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Neuropathy Impairment Score (NIS) at Month 12","description":"The NIS is a composite neurologic impairment score that assesses motor weakness (NIS-W), sensation (NIS-S) and reflexes (NIS-R) by physical exam. The minimum and maximum values are 0 and 244, respectively. A higher score indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Score at Month 12","description":"The Norfolk QoL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that is sensitive to the different features of diabetic neuropathy - small fiber, large fiber, and autonomic nerve function. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"4.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Month 12","description":"The R-ODS is comprised of a 24-item linearly weighted scale that specifically captures activity and social participation limitations. The minimum and maximum values are 0 and 48, respectively. A higher score indicates a better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Composite Autonomic Symptom Score (COMPASS-31) at Month 12","description":"The COMPASS-31 questionnaire is a measure of autonomic neuropathy symptoms. The questions evaluate 6 autonomic domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor). The minimum and maximum values are 0 and 100, respectively. A higher score indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Modified Body Mass Index (mBMI) at Month 12","description":"Nutritional status of participants was evaluated using the mBMI, calculated as BMI (kg/m\\^2) multiplied by albumin (g/L). An increase from baseline in mBMI suggests improvement, and a decrease from baseline suggests worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"21.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"An AE is any untoward medical occurrence in a participant or clinical investigational patient administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":23},"commonTop":["Diarrhoea","Infusion related reaction","Oedema peripheral","Back pain","Fatigue"]}}}